目的 探討大株紅景天注射液聯(lián)合地爾硫䓬治療冠心病心絞痛的臨床療效。方法 選取2020年1月-2020年7月在鄭州大學(xué)第五附屬醫(yī)院診治的142例冠心病心絞痛患者，隨機(jī)分為對(duì)照組和治療組，每組各71例。對(duì)照組口服鹽酸地爾硫䓬片，1片/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注大株紅景天注射液，每次10 mL加入5%葡萄糖注射液250 mL，1次/d。兩組患者均治療10 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者心絞痛發(fā)作情況、硝酸甘油用量、24 h動(dòng)態(tài)心電圖變化，及超敏C反應(yīng)蛋白（hs-CRP）、可溶性細(xì)胞間黏附分子1（sICAM-1）、白細(xì)胞介素-6（IL-6）、基質(zhì)金屬蛋白酶-2（MMP-2）、超氧化物歧化酶（SOD）、丙二醛（MDA）和晚期糖基化終末產(chǎn)物（AGEs）水平。結(jié)果 治療后，對(duì)照組臨床有效率為80.28%，顯著低于治療組的92.96%（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)、心絞痛每次持續(xù)時(shí)間、硝酸甘油用藥總量均顯著下降（P<0.05），且治療組下降幅度更明顯（P<0.05）。治療后，治療組缺血發(fā)作次數(shù)、缺血最長(zhǎng)持續(xù)時(shí)間、缺血總時(shí)間、室性早搏次數(shù)明顯低于對(duì)照組（P<0.05）。治療后，兩組患者h(yuǎn)s-CRP、sICAM-1、IL-6、MMP-2水平均顯著下降（P<0.05），且治療組下降更明顯（P<0.05）。治療后，兩組患者SOD顯著升高，MDA、AGEs顯著下降（P<0.05），且治療組患者改善更明顯（P<0.05）。結(jié)論 大株紅景天注射液聯(lián)合地爾硫䓬治療冠心病心絞痛具有良好的臨床療效，可有效改善患者臨床癥狀，改善冠脈供血，控制炎癥反應(yīng)，抑制氧化應(yīng)激反應(yīng)，且安全性較高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Dazhuhongjingtian Injection combined with diltiazem in treatment of angina pectoris of coronary heart disease. Methods Patients (142 cases) with angina pectoris of coronary heart disease in the Fifth Affiliated Hospital of Zhengzhou University from January 2020 to July 2020 were randomly divided into control and treatment groups, and each group had 71 cases. Patients in the control group were po administered with Diltiazem Hydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were iv administered with Dazhuhongjingtian Injection on the basis of the control group, 10 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the incidence of angina pectoris, dosage of nitroglycerin, and 24 h ambulatory electrocardiogram, the levels of hs-CRP, sICAM-1, IL-6, MMP-2, SOD, MDA, and AGEs in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.28%, which was significantly lower than 92.96% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the incidence of angina pectoris, dosage of nitroglycerin, and 24 h ambulatory electrocardiogram in two groups were significantly decreased (P<0.05), and the indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the frequency of ischemic attacks, the longest duration of ischemia, the total time of ischemia, the frequency of ventricular premature beats in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of hs-CRP, sICAM-1, IL-6 and MMP-2 in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the SOD levels in two groups were significantly increased, but the MDA and AGEs levels were significantly decreased (P<0.05), and the improvement of SOD, MDA, and AGEs in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Dazhuhongjingtian Injection combined with diltiazem has good clinical efficacy in treatment of angina pectoris of coronary heart disease, can effectively improve the clinical symptoms, improve coronary blood supply, control inflammatory reaction, inhibit oxidative stress reaction, and has high safety, which has a certain clinical application value.

R972